Merus (MRUS) Competitors $56.04 +0.99 (+1.80%) As of 11:10 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, and ROIVShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Merus (NASDAQ:MRUS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Is MRUS or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Merus' net margin of -680.61%. Intra-Cellular Therapies' return on equity of -9.93% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Merus-680.61% -38.89% -31.16% Intra-Cellular Therapies -14.07%-9.93%-8.38% Do analysts recommend MRUS or ITCI? Merus presently has a consensus target price of $85.83, indicating a potential upside of 53.16%. Intra-Cellular Therapies has a consensus target price of $109.70, indicating a potential downside of 16.81%. Given Merus' stronger consensus rating and higher probable upside, equities analysts plainly believe Merus is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Do institutionals and insiders hold more shares of MRUS or ITCI? 96.1% of Merus shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 4.6% of Merus shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, MRUS or ITCI? Merus has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Which has stronger valuation and earnings, MRUS or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Merus. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$54.73M70.87-$154.94M-$4.08-13.74Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Does the MarketBeat Community prefer MRUS or ITCI? Intra-Cellular Therapies received 155 more outperform votes than Merus when rated by MarketBeat users. However, 67.96% of users gave Merus an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformMerusOutperform Votes36767.96% Underperform Votes17332.04% Intra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% Does the media favor MRUS or ITCI? In the previous week, Merus had 6 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 6 mentions for Merus and 0 mentions for Intra-Cellular Therapies. Merus' average media sentiment score of 0.74 beat Intra-Cellular Therapies' score of 0.00 indicating that Merus is being referred to more favorably in the media. Company Overall Sentiment Merus Positive Intra-Cellular Therapies Neutral SummaryMerus beats Intra-Cellular Therapies on 12 of the 19 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.88B$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-14.198.8527.2320.02Price / Sales70.87256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book9.086.617.124.70Net Income-$154.94M$143.93M$3.23B$247.97M7 Day Performance0.05%3.84%2.74%2.64%1 Month Performance32.14%11.14%8.94%6.39%1 Year Performance-1.09%4.35%31.59%13.95% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus3.0996 of 5 stars$56.04+1.8%$85.83+53.2%-3.6%$3.88B$54.73M-14.1937ITCIIntra-Cellular Therapies0.9173 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.7583 of 5 stars$21.77+3.9%$39.17+79.9%-17.2%$13.96B$3.12B12.511,660Gap UpSMMTSummit Therapeutics2.902 of 5 stars$17.73-2.7%$37.40+110.9%+159.7%$13.17B$700K-63.32110Trending NewsAnalyst UpgradeAnalyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.4917 of 5 stars$14.73+0.0%$17.00+15.4%+10.6%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.5658 of 5 stars$175.69+7.9%$216.07+23.0%+30.2%$10.71B$368.70M-24.75640Analyst ForecastAnalyst RevisionMRNAModerna4.527 of 5 stars$27.05+1.8%$53.58+98.1%-81.3%$10.46B$3.14B-2.913,900VTRSViatris2.5528 of 5 stars$8.69-1.1%$10.50+20.8%-15.6%$10.20B$14.33B-11.7437,000QGENQiagen3.3487 of 5 stars$44.89-0.5%$48.42+7.9%+9.2%$9.98B$2.00B125.006,030BPMCBlueprint Medicines1.1701 of 5 stars$127.79+26.1%$125.69-1.6%+21.4%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.4436 of 5 stars$11.17+1.6%$17.50+56.7%+6.7%$7.97B$29.05M-74.46860 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
